‹ Go back to overview

SADC M&E Plan for Pharmaceutical Business Plan

South Africa, Botswana, Zimbabwe, Swaziland, Lesotho, Mozambique, Zambia, Malawi, The Democratic Republic of The Congo, Namibia, Madagascar, Angola, Mauritius, Seychelles, Tanzania
Field of Expertise:
Medical Products, Technologies; Policy/Strategy/DRA; Drug Regulatory Authority
Narrative description of project:
At the end of 2007, the Southern African Development Community (SADC) adopted its Pharmaceutical Business Plan, which is a roadmap designed to “enhance the capacities of Member States to effectively prevent and treat diseases that are of major concern to public health in the region through improving access to quality essential medicines”.
DFID Southern Africa (DFID-SA) wished to assist SADC with the implementation of this business plan and designed the Southern Africa Regional Programme on Access to Medicines and Diagnostics (SARPAM) in response. Its purpose is “to strengthen capacity across the SADC region in order to improve the availability, affordability and quality of essential medicines and diagnostics” (in line with MDG 8, Target 17). The programme is aligned with and builds on SADC’s Pharmaceutical Business Plan and will enable the SADC Secretariat, Member States and other stakeholders to implement aspects of the Pharmaceutical Business Plan alongside the implementation of other initiatives to expand access to quality assured medicines in the Southern African region.